Voyager Therapeutics Inc (VYGR) — Cash Flow-to-Debt Ratio
Voyager Therapeutics Inc (VYGR) has a Cash Flow-to-Debt Ratio of -0.45x as of September 2025, meaning its operating cash flow of $-31.05 Million could theoretically repay 0% of its total liabilities ($68.49 Million) in one year. See Voyager Therapeutics Inc (VYGR) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Voyager Therapeutics Inc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Voyager Therapeutics Inc across 12 annual periods. Also explore VYGR shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Voyager Therapeutics Inc (2013–2024)
Year-by-year debt coverage analysis for Voyager Therapeutics Inc. For market capitalisation and broader financial context, see VYGR market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.16x | $-15.31 Million | $93.29 Million | ▼ -124.2% |
| 2023 | 0.68x | $77.92 Million | $114.96 Million | ▲ +643.7% |
| 2022 | -0.12x | $-12.51 Million | $100.34 Million | ▲ +77.0% |
| 2021 | -0.54x | $-53.52 Million | $98.80 Million | ▲ +39.9% |
| 2020 | -0.90x | $-96.72 Million | $107.26 Million | ▼ -572.9% |
| 2019 | 0.19x | $48.67 Million | $255.25 Million | ▲ +256.7% |
| 2018 | -0.12x | $-15.89 Million | $130.58 Million | ▲ +90.0% |
| 2017 | -1.22x | $-61.35 Million | $50.43 Million | ▼ -53.6% |
| 2016 | -0.79x | $-42.48 Million | $53.64 Million | ▼ -215.8% |
| 2015 | 0.68x | $41.30 Million | $60.38 Million | ▲ +159.4% |
| 2014 | -1.15x | $-11.92 Million | $10.35 Million | ▲ +15.9% |
| 2013 | -1.37x | $-5.45 Million | $3.98 Million | — |